Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance olaparib vs placebo in gBRCA-mutated metastatic pancreatic cancer after platinum chemotherapy
2014-001589-85Phase 3Unknown
- Sponsor
- AstraZeneca
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic cancer (PC) comparing Olaparib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival by BICR. Status: unknown.
02
Drugs
olaparib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2014-001589-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001589-85.